We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving landscape of Alzheimer's treatments.
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks to ...
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Memory Treatment Centers to Study Brain Volume Changes in Alzheimer's Patients on Anti-Amyloid Drugs
The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.
Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a ...
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.
Japan’s Ministry of Health, Labour and Welfare granted new drug approvals and expanded indications for conditions like cancer, insomnia and Alzheimer’s disease (AD) Sept. 24, including Eli Lilly and ...
A “game-changing” new Alzheimer’s treatment was approved for use in the US by “independent” scientists who had received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback